On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.

The agreement grants Lilly an exclusive worldwide license for the development, manufacturing, and commercialization of novel oral therapeutics in preclinical development for certain indications. In addition, Insilico and Lilly will collaborate on multiple R&D programs focused on targets selected by Lilly, by combining Insilico's Pharma.AI platforms with Lilly's development capabilities and deep disease-area expertise.

Under the terms of the agreement, Insilico is eligible to receive a $115 million upfront payment, followed by development, regulatory, and commercial milestones that could bring the total deal value to approximately $2.75 billion, plus tiered royalties on future sales.

The Wilson Sonsini team that advised Insilico included Alex Key, Kexi Wang, Kimberley Biagioli, Michelle Yost Hale, and John Sack.

For more information, please see Insilico's news release. Additional coverage can be found on Reuters and BioSpace.